<?xml version="1.0" encoding="UTF-8"?>
<p>BVGH facilitated a collaboration between two Member companies focused on blockade of platelet-activating factor receptor (PAFR) to treat dengue. Previous studies showed that treatment with the PAFR antagonist modipafant delayed and decreased lethality in mice inoculated with the dengue virus [
 <xref rid="B35-tropicalmed-04-00053" ref-type="bibr">35</xref>]. 60P Pharmaceuticals, a company that specializes in drug development for tropical diseases, was interested in repurposing modipafant for treating dengue fever. Modipafant was under development by Pfizer, but was discontinued. Pfizer disclosed modipafant’s Investigator’s Brochure to 60P under confidentiality. An Investigator’s Brochure is a compilation of the clinical and nonclinical data on the investigational product(s) that is relevant to the study of the investigational product(s) in human subjects [
 <xref rid="B36-tropicalmed-04-00053" ref-type="bibr">36</xref>].
</p>
